Multi-program deal with revenue potential of $100 million per target

多项目方案，每个目标对象的收入潜力达1亿美元

SAN DIEGO

圣迭戈

,

，

Aug. 15, 2026

2026年8月15日

/PRNewswire/ --

/PRNewswire/ --

Aizen Therapeutics

艾森治疗公司

, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target..

，一家专注于开发口服生物制剂的AI原生生物技术公司，今日宣布与一家总部位于圣地亚哥的上市生物技术公司达成多项计划合作，利用其DaX™基础模型设计口服肽类治疗药物。该协议为Aizen带来了数百万美元的初始收入，并为每个提名靶点提供高达1亿美元的里程碑付款。

'Oral biologics represent a new frontier in drug development. We are focused on designing oral peptides for validated biological targets that can deliver an improved therapeutic index, reduced systemic toxicity, and enhanced target engagement in a pill,' said Ajay Kshatriya, Chief Executive Officer and co-founder of Aizen Therapeutics.

“口服生物制剂代表了药物开发的新前沿。我们专注于为经过验证的生物靶点设计口服肽，以期在药片中实现更优的治疗指数、降低全身毒性并增强靶点结合。”Aizen Therapeutics 首席执行官兼联合创始人 Ajay Kshatriya 表示。

'We are excited to collaborate with a world-class partner to develop proof of activity with our DaX platform for well-known disease-relevant targets in immunology and neurology indications.'.

“我们很高兴与世界级合作伙伴携手，利用我们的DaX平台针对免疫学和神经学适应症中知名的疾病相关靶点开发生物活性验证。”

Aizen was spun out from Caltech, with a first-in-class computational design model for peptides. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at ten times the scale of traditional ncAA discovery methods..

Aizen 源自加州理工学院，拥有业界首创的肽计算设计模型。DaX 平台已在数百万个独特标注的分子和受体上接受训练，能够以十倍于传统非天然氨基酸（ncAA）发现方法的规模，探索非天然氨基酸肽的化学空间。

'With technical challenges in data scarcity and chemical complexity,

面临数据稀缺和化学复杂性的技术挑战，

de novo

从头开始

peptide design is the frontier of Drug Discovery AI,' said

“肽设计是药物发现人工智能的前沿领域，”

David Van Valen, MD, PhD

大卫·范·瓦伦，医学博士，哲学博士

, Aizen Scientific Founder and Caltech Professor. 'This collaboration represents a meaningful step for the field, pairing AI peptide design with a world-class biopharma category leader to advance molecules into medicines.'

，Aizen Scientific 创始人兼加州理工学院教授。“此次合作代表了该领域有意义的一步，将人工智能肽设计与世界一流的生物制药类别领导者相结合，推动分子转化为药物。”

About Aizen Therapeutics

关于 Aizen Therapeutics

Aizen is an AI-native biotechnology company pioneering oral peptides to transform the lives of patients and families burdened by chronic immune disorders. Powered by DaX—a foundational AI platform developed by Caltech faculty—we design de novo peptides that transcend natural biology through the expansive chemical landscape of non-canonical amino acids (ncAA)..

Aizen 是一家原生人工智能生物技术公司，致力于开创口服肽疗法，以改善受慢性免疫疾病困扰的患者及其家庭的生活。依托由加州理工学院教师团队开发的基础人工智能平台 DaX，我们利用非经典氨基酸（ncAA）的广阔化学空间，设计从头合成的新型肽，超越自然生物学的局限。

Headquartered in San Diego and venture-backed, Aizen is advancing a proprietary pipeline of gut-restricted and systemic oral biologics. Simultaneously, we collaborate with global biopharma to deploy our platform against high-value technical frontiers, synthesizing the precision of antibodies with the stability and oral delivery of small molecules..

Aizen 总部位于圣地亚哥，由风险投资支持，正在推进其专有的肠道限制性及系统性口服生物制剂研发管线。同时，我们与全球生物制药企业合作，利用我们的平台攻克高价值的技术前沿，将抗体的精确性与小分子的稳定性及口服递送优势相结合。

SOURCE Aizen Therapeutics

来源：Aizen Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示